UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Retraction Note to: LncRNA PVT1 triggers Cyto-protective autophagy and promotes pancreatic ductal adenocarcinoma development via the miR-20a-5p/ULK1 Axis

Molecular cancer, 2022-11, Vol.21 (1), p.1-209, Article 209

2022

Volltextzugriff (PDF)

Corrigendum: Effect of itraconazole on the safety and pharmacokinetics of antitumor SHR6390

Frontiers in drug discovery, 2024-04, Vol.4

2024

Volltextzugriff (PDF)

Correction to: H3K27 acetylation activated long noncoding RNA RP11-162G10.5 promotes breast cancer progression via the YBX1/GLO1 axis

Cellular oncology (Dordrecht), 2023-06, Vol.46 (3), p.799-799

2023

Volltextzugriff (PDF)

Effect of itraconazole on the safety and pharmacokinetics of antitumor SHR6390

Frontiers in drug discovery, 2022-09, Vol.2

2022

Volltextzugriff (PDF)

RETRACTED ARTICLE: LncRNA PVT1 triggers Cyto-protective autophagy and promotes pancreatic ductal adenocarcinoma development via the miR-20a-5p/ULK1 Axis

Molecular cancer, 2018-07, Vol.17 (1), Article 98

2018

Volltextzugriff (PDF)

763 Initial results from phase I dose escalation trial of CAN1012 in patients with solid tumor malignancies

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A858-A858

2023

Volltextzugriff (PDF)

A Phase I, Randomized, Single-Ascending-Dose, Multiple-Dose, and Food-Effect Trial of the Safety, Efficacy, and Pharmacokinetics of Topiroxostat in Healthy Chinese Participants

BIO Integration, 2022, Vol.3 (3)

2022

Volltextzugriff (PDF)

RNA ac4C modification in cancer: Unraveling multifaceted roles and promising therapeutic horizons

Cancer letters, 2024-10, Vol.601, p.217159, Article 217159

2024

Volltextzugriff (PDF)

Unraveling the unfolded protein response signature: implications for tumor immune microenvironment heterogeneity and clinical prognosis in stomach cancer

Aging (Albany, NY.), 2024-05, Vol.16 (9), p.7818-7844

2024

Volltextzugriff (PDF)

Expression of Concern: Reduced miR-128 in Breast Tumor–Initiating Cells Induces Chemotherapeutic Resistance via Bmi-1 and ABCC5

Clinical cancer research, 2024-07, Vol.30 (13), p.2847-2847

2024

Volltextzugriff (PDF)

A single-arm, multicenter, phase II study of utidelone in advanced solid tumors: Efficacy data from screening and the expansion cohort assessing utidelone plus sintilimab and oxaliplatin for advanced gastric cancer

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e16055-e16055

2024

Volltextzugriff (PDF)

Phase I study of LZM005, a HER2 antibody, as monotherapy or in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1042-1042

2021

Volltextzugriff (PDF)

let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells

Cell, 2007-12, Vol.131 (6), p.1109-1123

2007

Volltextzugriff (PDF)

A novel oral paclitaxel and HM10381 (oraxel)-treated metastatic breast cancer: A phase I study (KX-ORAX-CN-007)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.1104-1104

2022

Volltextzugriff (PDF)

Cyclin-dependent kinases 4 and 6 inhibitors in HR+/HER2- advanced breast cancer

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e13048-e13048

2018

Volltextzugriff (PDF)

Abstract P2-13-35: Pyrotinib combined with fulvestrant in women with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer: A single-arm phase II clinical trial

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P2-P2-13-35

2022

Volltextzugriff (PDF)

PD-L1 and neutrophil to lymphocyte ratio (NLR) as predictive panel of prognosis in bladder cancer

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e17040-e17040

2020

Volltextzugriff (PDF)

Trastuzumab combined with doublet or single-agent chemotherapy as a first-line treatment for HER2-positive metastatic breast cancer

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e12511-e12511

2017

Volltextzugriff (PDF)

Locoregional surgery of the primary tumor in stage IV breast cancer patients

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.566-566

2017

Volltextzugriff (PDF)

LncRNA Uc003xsl.1-Mediated Activation of the NFκB/IL8 Axis Promotes Progression of Triple-Negative Breast Cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4), p.556-570

2022

Volltextzugriff (PDF)

Surrogate end points for overall survival in patients with advanced non-small-cell lung cancer in trials of immunotherapy

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14122-e14122

2019

Volltextzugriff (PDF)

Different maintenance strategies versus observation in patients with hormone receptor-positive metastatic breast cancer after first-line chemotherapy: A real-world study and meta-analysis

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e12529-e12529

2019

Volltextzugriff (PDF)

Tolerability and effectiveness of fulvestrant as first-line endocrine therapy in unselected patients with advanced breast cancer (ABC): Results of a multicenter, single arm, non-interventional study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e13061-e13061

2023

Volltextzugriff (PDF)

Claudin-9 ( promotes gastric cancer progression by enhancing the glycolysis pathway and facilitating PD-L1 lactylation to suppress CD8+ T cell anti-tumor immunity

Cancer pathogenesis and therapy, 2024-09

2024

Volltextzugriff (PDF)

ac 4 C RNA modification in Cancer: Unraveling Multifaceted Roles and Promising Therapeutic Horizons

Cancer letters, 2024-08, p.217159

2024

Volltextzugriff (PDF)

1 – 25 von 81

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieNature Communications

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(70)
Mit Volltextzugriff
(66)

Publikationsform

Artikel
(80)
Tagungsberichte
(1)

Sprache

Englisch
(79)
Chinesisch
(2)

Erscheinungsjahr

n.n

Thema

Female
(5)
Humans
(5)
Cancer
(4)
Cancer Metastasis
(4)
Middle Aged
(4)
Drug-Drug Interaction
(3)
Adult
(2)
Animals
(2)
Breast Cancer
(2)
Cell Line, Tumor
(2)
Development And Progression
(2)
Food Effect
(2)
Gene Expression Regulation, Neoplastic
(2)
Healthy Subjects
(2)
Hyperuricemia
(2)
Itraconazole
(2)
Male
(2)
Mice
(2)
Pharmacodynamics
(2)
Pharmacokinetic
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Retraction Note to: LncRNA PVT1 triggers Cyto-protective autophagy and promotes pancreatic ductal adenocarcinoma development via the miR-20a-5p/ULK1 Axis

Corrigendum: Effect of itraconazole on the safety and pharmacokinetics of antitumor SHR6390

Correction to: H3K27 acetylation activated long noncoding RNA RP11-162G10.5 promotes breast cancer progression via the YBX1/GLO1 axis

Effect of itraconazole on the safety and pharmacokinetics of antitumor SHR6390

RETRACTED ARTICLE: LncRNA PVT1 triggers Cyto-protective autophagy and promotes pancreatic ductal adenocarcinoma development via the miR-20a-5p/ULK1 Axis

763 Initial results from phase I dose escalation trial of CAN1012 in patients with solid tumor malignancies

A Phase I, Randomized, Single-Ascending-Dose, Multiple-Dose, and Food-Effect Trial of the Safety, Efficacy, and Pharmacokinetics of Topiroxostat in Healthy Chinese Participants

RNA ac4C modification in cancer: Unraveling multifaceted roles and promising therapeutic horizons

Unraveling the unfolded protein response signature: implications for tumor immune microenvironment heterogeneity and clinical prognosis in stomach cancer

Expression of Concern: Reduced miR-128 in Breast Tumor–Initiating Cells Induces Chemotherapeutic Resistance via Bmi-1 and ABCC5

A single-arm, multicenter, phase II study of utidelone in advanced solid tumors: Efficacy data from screening and the expansion cohort assessing utidelone plus sintilimab and oxaliplatin for advanced gastric cancer

Phase I study of LZM005, a HER2 antibody, as monotherapy or in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer

let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells

A novel oral paclitaxel and HM10381 (oraxel)-treated metastatic breast cancer: A phase I study (KX-ORAX-CN-007)

Cyclin-dependent kinases 4 and 6 inhibitors in HR+/HER2- advanced breast cancer

Abstract P2-13-35: Pyrotinib combined with fulvestrant in women with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer: A single-arm phase II clinical trial

PD-L1 and neutrophil to lymphocyte ratio (NLR) as predictive panel of prognosis in bladder cancer

Trastuzumab combined with doublet or single-agent chemotherapy as a first-line treatment for HER2-positive metastatic breast cancer

Locoregional surgery of the primary tumor in stage IV breast cancer patients

LncRNA Uc003xsl.1-Mediated Activation of the NFκB/IL8 Axis Promotes Progression of Triple-Negative Breast Cancer

Surrogate end points for overall survival in patients with advanced non-small-cell lung cancer in trials of immunotherapy

Different maintenance strategies versus observation in patients with hormone receptor-positive metastatic breast cancer after first-line chemotherapy: A real-world study and meta-analysis

Tolerability and effectiveness of fulvestrant as first-line endocrine therapy in unselected patients with advanced breast cancer (ABC): Results of a multicenter, single arm, non-interventional study

Claudin-9 ( promotes gastric cancer progression by enhancing the glycolysis pathway and facilitating PD-L1 lactylation to suppress CD8+ T cell anti-tumor immunity

ac 4 C RNA modification in Cancer: Unraveling Multifaceted Roles and Promising Therapeutic Horizons

Aktive Filter

Suchergebnisse filtern